CaptureSelect™ KappaXP Affinity Matrix
CaptureSelect™ KappaXP Affinity Matrix
Thermo Scientific™

CaptureSelect™ KappaXP Affinity Matrix

Thermo Scientific™ CaptureSelect™ KappaXP Affinity Matrix is the improved version of CaptureSelect KappaXL Affinity Matrix, with a significant increase in binding capacity for both whole kappa monoclonal antibodies and kappa Fab's.
Have Questions?
變更視圖buttonViewtableView
產品號碼Quantity
1943212250250 mL
29432120055 mL
294321201010 mL
294321205050 mL
194321201L1 L
194321205L5 L
6 選項
產品號碼 1943212250
價格 (HKD)/ 250 mL
-
Quantity:
250 mL

CaptureSelect KappaXP Affinity Matrix is the improved version of CaptureSelect KappaXL Affinity Matrix, with a significant increase in binding capacity for both whole kappa monoclonal antibodies and kappa Fab's. It enables efficient elution, even at pH 6.0, and demonstrates an improved stability for caustic cleaning agents. It is specific for human antibodies or antibody fragments, without cross-specificity to bovine antibody.

CaptureSelect KappaXP matrix recognizes the kappa light chain of human antibodies, enabling purification of all kappa-containing Ig's, Fab, and Fab2 fragments directly from complex sources and feed streams.

CaptureSelect KappaXP Affinity Matrix features include:

  • Purification of kappa monoclonal antibodies, Fab, and Fab2 fragments directly from complex source materials in a single step with high purity and yield
  • Mild elution for Fab fragments and antibodies
  • Human specific, no binding to bovine antibodies
  • Excellent scalability
  • Excellent pH stability up to 100 mM NaOH for limited exposure
  • Non–animal-derived

The high selectivity and high yields obtained using CaptureSelect KappaXP Affinity Matrix enable a robust and efficient purification process with excellent purity in one step.

Free of animal components

CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12 to 15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).

Main characteristics:

  • Matrix: agarose-based
  • Average particle size: 65 ± 10 μm
  • Ligand: CaptureSelect KappaXP affinity ligand
  • Ligand coupling method: epoxide immobilization of the ligand
  • Fab binding capacity: 20–30 g IgG Kappa-Fab/liter resin depending on flow rate, column height, and residence time
  • IgG binding capacity: 35–45 g IgG/liter resin depending on flow rate, column height, and residence time
  • Elution conditions: 20 mM citric acid or acetic acid, pH 3–4; 100 mM Tris, 1.5 M MgCl2, pH 6
  • Flow characteristics: 150–300 cm/h (up to 2 bar)
  • Formulation buffer: 20% (v/v) ethanol
規格
Flow Rate150 to 300 cm/hr. (Up to 2 bar)
MatrixAgarose-based
Shipping ConditionWet Ice
Particle Size65 ±10 μm
FormLiquid Suspension
Product LineCaptureSelect™
Quantity250 mL
TypeAffinity Matrix
Ligand TypeKappaXP affinity ligand
Stationary PhaseKappaXP
Unit Size250 mL
內容物與存放
Store in refrigerator (2°C to 8°C).